Covidien divests specialty chemicals business
This article was originally published in The Tan Sheet
The diversified device, medical supply and drug maker will divest its specialty chemicals business to an affiliate of New Mountain Capital LLC for $280 million under an agreement announced May 26. The division, which generated sales of $414 million in fiscal 2009, makes chemicals and related products for research and quality control labs, and for manufacturing in pharmaceutical, biotechnology and other industries. The sale is part of Covidien's strategy to sell businesses outside health care since its spin-off from Tyco in 2007
You may also be interested in...
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.